Literature DB >> 24960604

Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?

Stéphane Oudard1, Antoine Angelergues1.   

Abstract

Cabazitaxel, a next-generation taxane, retains its efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress on new androgen receptor (AR)-targeted agents such as abiraterone acetate or enzalutamide. These findings are reinforced by in vitro preclinical data confirming cross-resistance between abiraterone and enzalutamide, but not between cabazitaxel and AR-targeted agents.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24960604     DOI： 10.1038/nrurol.2014.144

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  8 in total

1.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Authors:  Maria Thadani-Mulero; Luigi Portella; Shihua Sun; Matthew Sung; Alexandre Matov; Robert L Vessella; Eva Corey; David M Nanus; Stephen R Plymate; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

Review 2.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

Review 3.  Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.

Authors:  John M Fitzpatrick; Ronald de Wit
Journal:  Eur Urol       Date:  2013-07-25       Impact factor: 20.096

4.  Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Authors:  John M Fitzpatrick; Joaquim Bellmunt; Karim Fizazi; Axel Heidenreich; Cora N Sternberg; Bertrand Tombal; Antonio Alcaraz; Amit Bahl; Sergio Bracarda; Giuseppe Di Lorenzo; Eleni Efstathiou; Stephen P Finn; Sophie Fosså; Silke Gillessen; Pirkko-Liisa Kellokumpu-Lehtinen; Frédéric E Lecouvet; Stephane Oudard; Theo M de Reijke; Craig N Robson; Maria De Santis; Bostjan Seruga; Ronald de Wit
Journal:  Eur J Cancer       Date:  2014-04-03       Impact factor: 9.162

5.  Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Authors:  Nader Al Nakouzi; Sylvestre Le Moulec; Laurence Albigès; Chris Wang; Philippe Beuzeboc; Marine Gross-Goupil; Thibault de La Motte Rouge; Aline Guillot; Dorota Gajda; Christophe Massard; Martin Gleave; Karim Fizazi; Yohann Loriot
Journal:  Eur Urol       Date:  2014-05-02       Impact factor: 20.096

6.  Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Authors:  Carmel J Pezaro; Aurelius G Omlin; Amelia Altavilla; David Lorente; Roberta Ferraldeschi; Diletta Bianchini; David Dearnaley; Christopher Parker; Johann S de Bono; Gerhardt Attard
Journal:  Eur Urol       Date:  2013-12-17       Impact factor: 20.096

7.  Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Authors:  Vivek K Arora; Emily Schenkein; Rajmohan Murali; Sumit K Subudhi; John Wongvipat; Minna D Balbas; Neel Shah; Ling Cai; Eleni Efstathiou; Chris Logothetis; Deyou Zheng; Charles L Sawyers
Journal:  Cell       Date:  2013-12-05       Impact factor: 41.582

8.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.